This U.S. serious spontaneous report from the mother of a consumer describes the occurrence of paranoia and 
hallucination, auditory in a 10-year-old male patient of unknown ethnicity taking Adderall XR (amphetamine 
aspartate, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate) for attention deficit 
hyperactivity disorder (ADHD). 
The patient had a concurrent medical history significant for seasonal allergy. The patient had no known drug 
allergies. 
The patient was taking unspecified allergy medication concomitantly. 
The patient commenced treatment with Adderall XR, 5 mg capsule daily in AUG-2012. Beginning in JAN-2013, the 
Print Time: 18-JUL-2014 02:07 PM If a field is blank, there is no data for that field Page 171 of 328 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
patient started acting paranoid, described as he refused to go upstairs because he was afraid and scared. In 2013, 
the patient began hearing voices. Treatment, if any, was not reported. Adderall XR therapy was discontinued in 
JUN-2013 for the summer and the events resolved in 2013. Adderall XR therapy had not been resumed at the time 
of this report. 
A causality assessment was not provided by the reporter.  
Shire considered the event of hallucination, auditory serious (medically significant). The event of paranoia was 
considered non-serious. 
Additional information has been requested. 
The-companys Pharmacovigilance Physician has assessed the event of hallucination and paranoid as possibly 
related to Adderall XR as there is a known association of psychotic episode at recommended dose of this drug. In 
addition, patient's symptom improved after discontinuation of this drug. This case does not alter the benefit/risk 
profile of the product.